Immunocore Holdings Limited (IMCR)
| Market Cap | 1.83B |
| Revenue (ttm) | 30.13M |
| Net Income (ttm) | n/a |
| Shares Out | 43.79M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $39.26 |
| Previous Close | $40.97 |
| Change ($) | -1.71 |
| Change (%) | -4.17% |
| Day's Open | 40.84 |
| Day's Range | 39.26 - 40.84 |
| Day's Volume | 7,079 |
| 52-Week Range | 30.92 - 61.99 |
P RESS RELEASE
Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary
The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...
About IMCR
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disea... [Read more...]
| Industry Biotechnology | IPO Date Feb 5, 2021 |
| CEO Bahija Jallal, Ph.D. | Employees 291 |
| Stock Exchange NASDAQ | Ticker Symbol IMCR |
Financial Performance
In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Immunocore is 51.50, which is an increase of 31.18% from the latest price.